Find us on:


Research Type
Reported as
Publication Type
Sort By
Total: 177
Low-dose Naltrexone Therapy for Psoriasis
Research Type Human Reported as Case Report/Series/Restrospective Study Date March 21, 2020 Authors L. B. Weinstock, J. Cottel, L. Aldridge, A. Egeberg Institution Washington University School of Medicine, University of Copenhagen Disease Psoriasis
Safe, inexpensive, and convenient psoriasis therapy is desirable. Two recent case reports suggested that low-dose naltrexone is effective. Cases from our practice are presented in order to further the evidence of efficacy and safety of low-dose naltrexone in the treatment of psoriasis. Patients included 13 females, 2 males; mean age 57 years; mean psoriasis duration 16 years. Of the patients, 8 had psoriatic arthritis. In the past, 5 had completely failed and 10 had partially responded t...
Naltrexone Hydrochloride 1.5-mg and 4.5-mg Capsules
Research Type Human Reported as Review Date March 19, 2020 Authors Loyd V. Allen, Jr., PhD Institution University of Oklahoma
Pharmacist Dr. Loyd V. Allen, Jr. reviews methods of preparation, uses, packaging, labeling, stability, and quality control of 1.5mg and 4.5mg capsules of low dose naltrexone. An interesting and unexpected effect of naltrexone is its action in pain relief for different disorders. A notable aspect of naltrexone use in pain patients is that the dose is only about one-tenth of the normal dose. Since naltrexone HCl is available in 50-mg tablets, low-dose naltrexone must be compounded for patients....
Low-dose naltrexone in Hailey-Hailey disease: the importance of dosing.
Research Type Human Reported as Review Date March 11, 2020 Authors P. Acharya, M. Mathur Institution Nepal College of Medical Sciences Disease Hailey-Hailey
We read with great interest the study by Jasans-Barceló et al. where they report the response of low-dose naltrexone in 8 patients of HHD. One interesting observation we made in the article was the response of one patient to the standard higher dose (50 mg) of naltrexone. Two previous studies that used the 50mg dose in HHD patients (3 patients total) had failed to show any positive response....
Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway.
Research Type Animal Date March 11, 2020 Authors M. Ma, X. Wang, N. Liu, F. Shan, Y. Feng Institution China Medical University Disease Cancer (general), Colorectal Cancer
The incidence of colorectal cancer (CRC) is increasing annually worldwide. However, traditional chemotherapy has obvious side effects. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Therefore, the aim of this study was to explore the mechanisms underlying the inhibitory effect of LDN on CRC progression in vivo and in vitro. We found that expression of macrophage markers (F4/80, CD68) was increased in nude mice treated with LDN compared ...
Enkephalin Therapy Improves Relapsing-Remitting Multiple Sclerosis
Research Type Human Reported as Case Report/Series/Restrospective Study Date January 28, 2020 Authors Chirag L. Patel, Ian S. Zagon, Gary A. Thomas and Patricia J. McLaughlin Institution Penn State University Disease MS (Multiple Sclerosis)
Multiple sclerosis (MS) is accompanied by decreases in serum endogenous enkephalin/endorphins and alterations in inflammatory cytokines. This retrospective analysis of serum levels was conducted in 53 patients with established relapsing-remitting MS treated with the disease-modifying therapies (DMT) glatiramer acetate, dimethyl fumarate or with the biotherapeutic low dose naltrexone (LDN) to elevate enkephalins, an off-label alternative. Opioid growth factor (OGF), an inhibitory endogenous opioi...
The Lowdown on Low-Dose Naltrexone
Research Type Human Reported as Review Date January 27, 2020 Authors Nadine Shabeeb Institution University of Wisconsin Disease Psoriasis
Low-dose naltrexone (LDN) has become a hot topic in many fields of medicine, including dermatology. It has gained popularity as an alternative, off-label treatment that works by targeting inflammation. Patients may ask you about LDN as a treatment option for a variety of inflammatory skin conditions, specifically in comparison to more traditional systemic treatments. It is important for dermatologists to know what LDN is, how it works, how to prescribe it, and what side effects should be monitor...
Improvement of Hailey-Hailey disease with low-dose naltrexone
Research Type Human Date January 07, 2020 Authors M. Jasans‐Barceló P. Curman L. Hagströmer J.D. Wikstrom D. Sairaf Institution Södersjukhuset Hospital, Karolinska Institute Disease Hailey-Hailey
Hailey-Hailey disease (HHD), or familial benign pemphigus, is a rare autosomal dominant acantholytic dermatosis characterized by blistering, and erythematous, erosive and macerated plaques located primarily in intertriginous areas. Secondary bacterial and viral infections are common. There is no "gold standard" treatment, although many therapeutic modalities have been proposed....
Low-Dose Naltrexone reduces symptoms in Stiff-Person Syndrome
Research Type Human Reported as Case Report/Series/Restrospective Study Date January 07, 2020 Authors Mauro Zappaterra, Elizabeth Shouse, Reed Loring Levine Institution Synovation Medical Group, VA Greater Los Angeles Healthcare System, Harmonae Psychological Services, Inc. Disease SPS (Stiff Person Syndrome)
Stiff-Person Syndrome (SPS) is a rare neurologic disorder characterized by severe and progressively worsening muscle stiffness and rigidity. SPS can be very painful due to unpredictable muscle spasms which can be triggered by various stimuli, such as noise, touch, or emotional experiences. There is thought to be an autoimmune component to the disorder. We present the case of a 59-year-old woman diagnosed with SPS who appears to have experienced a dramatic reduction in her symptoms after being tr...
Low-dose naltrexone as a treatment for chronic fatigue syndrome
Research Type Human Reported as Case Report/Series/Restrospective Study Date January 06, 2020 Authors MJ Bolton, BP Chapman, H van Marwijk Institution Brighton and Sussex Medical School Disease CFS
Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. Although only small-scale clinical trials have been performed, these suggest efficacy in several diseases including Crohn's disease, fibromyalgia and Gulf War Illness. Despite numerous internet reports of response to low-dose naltrexone (LDN), no clinical trials exist in people with chronic fatigue syndrome. This condition is characterised by chronic profound fatigue, poste...
The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune response
Research Type Animal Reported as Clinical Trial Date December 14, 2019 Authors Alshimaa Aboalsoud, Sabah H. El-Ghaiesh, Fleur F. Abd Elmonem, Mohammed L.Salem, Mohamed N. Abdel Rahmana Institution Tanta University, University of Tabuk, Bisha University Disease Cancer (general)
AIMS: Cancer is a major worldwide health problem. Cancer cells express opioid growth factor (OGF) which controls their growth. Naltrexone in low dose (LDN) blocks opioid receptors intermittently and controls the replication of cancer cells. The aim of this study was to investigate the effect of LDN and its chemotherapeutic additive effect on the growth of solid Ehrlich carcinoma in mice with focus on the OGFr and immune responses. MAIN METHODS: Sixty female Swiss albino mice were assigned into ...